Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus

• US 6,506,724 B1
• Filed: 06/01/1999
• Issued: 01/14/2003
• Est. Priority Date: 06/01/1999
• Status: Expired due to Term

• Current Assignee: Astrazeneca Pharmaceuticals LP (Astrazeneca PLC)
• Original Assignee: Amylin Pharmaceuticals Incorporated (Bristol-Myers Squibb Company)
• Inventors: Prickett, Kathryn S., Hiles, Richard A.
• Primary Examiner(s): CELSA, BENNETT M
• Application Number:
  US09/323,867
• Time in Patent Office: 1,323 Days
• Field of Search: 574/2, 574/3, 574/7, 574/12, 574/866, 530/300, 530/324, 530/325
• US Class Current: 514/5.9
• CPC Class Codes: A61K 38/2278 Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics

Abstract

Methods for treating gestational diabetes which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that lower blood glucose levels.

Claims

1. A method for reducing blood glucose level of a subject having gestational diabetes mellitus comprising administering to said subject a therapeutically effective amount of an exendin or an exendin agonist, wherein said exendin agonist is a peptide.

2. The method according to claim 1 wherein said exendin or exendin agonist is administered continuously.

3. The method according to claim 1 wherein said administration is by injection.

4. The method according to claim 3 wherein said injection is a subcutaneous injection.

5. The method according to claim 1 wherein about 1 μ

g-30 μ

g to about 1 mg of the exendin or exendin agonist is administered per day.

6. The method according to claim 1 wherein about 1 μ

g-30 μ

g to about 500 μ

g of the exendin or exendin agonist is administered per day.

7. The method according to claim 1 wherein about 1 μ

g-30 μ

g to about 100 μ

g of the exendin or exendin agonist is administered per day.

8. The method according to claim 1, wherein about 3 μ

g to about 50 μ

g of the exendin or exendin agonist is administered per day.

9. The method of claim 1 wherein said subject is human.

10. The method according to any of claims 2-9 wherein said exendin is exendin-4.

11. The method according to any of claims 2-9, further comprising administering a therapeutically effective amount of one or more compounds selected from the group consisting of an insulin and an amylin agonist.

12. The method of claim 11, further comprising administering a therapeutically effective amount of an insulin.

13. The method of claim 11, further comprising administering a therapeutically effective amount of an amylin agonist.